1. Tepper SJ, Dahlöf CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004;44:856–64.
2. Lewis DW et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002;59:490–8.
3. Martens D, Oster I, Gottschlling S, et al. Cerebral MRI and EEG studies in the initial management of pediatric headaches. Swiss Med Wkly 2012;142:w13625.
4. Linder SL. Understanding the comprehensive pediatric headache examination. Pediatr Ann 2005;34:442–6.
5. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.
6. Senbil N, Gürer YK, Uner C, et al. Sinusitis in children and adolescents with chronic or recurrent headache: a case-control study. J Headache Pain 2008;9:33–6.
7. Gelfand AA, Reider AC, Goadsby PJ. Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. Neurology 2013;81:431–6.
8. Blau JN. Water deprivation: a new migraine precipitant. Headache 2005;45:757–9.
9. Martins IP, Gouveia RG. More on water and migraine. Cephalalgia 2007;27:372–4.
10. Hämäläinen ML, Hoppu K, Valkeila E, et al. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48:103–7.
11. Lewis DW, Kellsein D, Sahl G, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002;42:780–6.
12. Lipton RB, Golstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache 2005;45:283–92.
13. Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008;48:1326–36.
14. Ahonen K, Hämäläinen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006;67:1135–40.
15. Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia 2012;32:750–65.
16. Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002;42:49–55.
17. Hewitt DJ, Pearlman E, Hämäläinen M, et al. Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs. Headache 2013;53:104–17.
18. Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012;129:e1411–20.
19. McDonald SA, Hershey AD, Pearlman E, et al. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents. Headache 2011;51:1374-87.
20. Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007; 120:390–6.
21. Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract 2000;54:466–9.
22. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000;106:989–97.
23. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000;22:1533–46.
24. Ahonen K, Hämäläinen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004;62:883–7.
25. Natarajan S, Jabbour JT, Webster CJ, et al. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache 2004;44:969–77.
26. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006;46:212–22.
27. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 1997;48:1100–3.
28. Fujita M, Sato K, Nishioka H, et al. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia 2014;34:365–75.
29. Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007;47:511–8.
30. Rothner A. Efficacy and safety of naratriptan tablets in adolescent migraine [abstract]. J Neurol Sci 1997;150:S106.
31. Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol 2004;44:1158–65.
32. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 2011;15:70–8.
33. Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:1304–12.
34. Lakshmi CV, Singhi P, Malhi P, et al. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22:829–35.
35. Lewis D, Winner P, Saper J, et al.Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 2009;123:924–34.
36. Hershey AD, Powers SW, Vockell AL, et al. Effectiveness of topiramate in the prevention of childhood headaches. Headache 2002;42:810–8.
37. Campistol J, Campos J, Casas C, et al. Topiramate in the prophylactic treatment of migraine in children. J Child Neurol 2005;20:251–3.
38. Unalp A, Uran N, Oztürk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol 2008;23:1377–81.
39. Cruz MJ, Valencia I, Legido A, et al. Efficacy and tolerability of topiramate in pediatric migraine. Pediatr Neurol 2009;41:167–70.
40. Kim H, Byun SH, Kim JS, et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur J Paediatr Neurol 2013;17:45–9.
41. Fallah R, Divanizadeh MS, Karimi M, et al. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr 2013;80:920–4.
42. Tonekaboni SH, Ghazavi A, Fayyazi A, et al. Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J Child Neurol 2013;7:9–14.
43. Hershey AD, Powers SW, Coffey CS, et al. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double blinded, placebo controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in prevention of childhood and adolescent migraine. Headache 2013;53:799–816.
44. Hershey AD, Powers SW, Bentti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000;40:539–49.
45. Lewis DW, Diamond S, Scott D, et al. Prophylactic treatment of pediatric migraine. Headache 2004;44:230–7.
46. Caruso JM, Brown WD, Exil G, et al. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 2000 Sep;40:672–6.
47. Pakalnis A, Greenberg G, Drake ME Jr, et al. Pediatric migraine prophylaxis with divalproex. J Child Neurol 2001;16:731–4.
48. Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. Headache 2002;42:819–22.
49. Miller GS. Efficacy and safety of levetiracetem in pediatric migraine. Headache 2004;44:238–43.
50. Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine--an open label study. Headache 2007;43:427–30.
51. Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache 2006;46:804–7.
52. Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48:1012–25.
53. Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurol 1974;50:109–15.
54. Forsythe WI, Gillies D, Sills MA. Propanolol (‘Inderal’) in the treatment of childhood migraine. Dev Med Child Neurol 1984;26:737–41.
55. Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics 1987;79:593–7.
56. Sorge F, DeSimone R, Marano E, et al. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled crossover study. Cephalalgia 1988;8:1–6.
57. Guidetti V, Moscato D, Ottaviano S, et al. Flunarizine and migraine in childhood: an evaluation of endocrine function. Cephalalgia 1987;7:263–6.
58. Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and complementary treatments for episodic migraine treatment in adults: Report of the quality standards subcommittee of the American Academy of Neurology and American Headache Society. Neurology 2012; 78:1346–53.
59. Oelkers-Ax R, Leins A, Parzer P, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain 2008;12:301–13.
60. Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005;45:196–203.
61. Hershey AD, Powers SW, Vockell AL, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47:73–80.
62. Slater SK, Nelson TD, Kabbouche MA, et al. A randomized, double-blind, crossover, add-on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31: 897–905.
63. Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003;43:601–10.
64. Castelli S, Meossi C, Domenici R, et al. [Magnesium in the prophylaxis of primary headache and other periodic disorders in children]. Pediatr Med Chir 1993;15:481–8. Italian.
65. Condò M, Posar A, Arbizzani A, et al. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009;10:361–5.
66. MacLennan SC, Wade FM, Forrest KM, et al. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol 2008;23:1300–4.
67. Bruijn J, Duivenvoorden H, Passchier J, et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia 2010;30:1426–34.
68. Robbins L. Precipitating factors in migraine: a retrospective review of 494 patients. Headache 1994;34:214–6.
69. Leviton A, Slack WV, Masek B, et al. A computerized behavioral assessment for children with headaches. Headache 1984;24:182–5.
70. Bruni O, Galli F, Guidetti V. Sleep hygiene and migraine in children and adolescents. Cephalalgia 1999;19 Suppl 25:57–9.
71. Lynch-Jordan AM, Sil S, Peugh J, et al. Differential changes in functional disability and pain intensity over the course of psychological treatment for children with chronic pain. Pain 2014;155:1955–61.
72. Eccleston C, Palermo TM, Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev 2014;5:CD003968.
73. Huguet A, McGrath PJ, Stinson J, et al. Efficacy of psychological treatment for headaches: an overview of systematic reviews and analysis of potential modifiers of treatment efficacy. Clin J Pain 2014;30:353–69.
74. Kropp P, Meyer B, Landgraf M, et al. Headache in children: update on biobehavioral treatments. Neuropediatrics 2013;44:20–4.
75. Kröner-Herwig B. Psychological treatments for pediatric headache. Expert Rev Neurother 2011;11:403–10.
76. Powers SW, Andrasik F. Biobehavioral treatment, disability, and psychological effects of pediatric headache. Pediatr Ann 2005;34:461–5.
77. Hermann C, Blanchard EB. Biofeedback in the treatment of headache and other childhood pain. Appl Psychophysiol Biofeedback 2002;27:143–62.
78. Powers SW, Kashikar-Zuck SM, Hershey AD, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA 2013;310:2622–30.
79. Smitherman TA, Wells RE, Ford SG. Emerging behavioral treatments for migraine. Curr Pain Headache Rep 2015;19:13.
80. Slater SK, O’Brien HL, Hershey AD, et al. Psychiatric comorbidity in pediatric chronic daily headache. Cephalalgia 2012;32: 1116–22.
81. Pavlovic JM, Stewart WF, Bruce CA, et al. Burden of migraine related to menses: results from the AMPP study. J Headache Pain 2015;16:24.
82. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351–3.
83. Granella F, Sances G, Allais G. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707–16.
84. Crawford MJ, Lehman L, Slater S, et al. Menstrual migraine in adolescents. Headache 2009;49:341–7.
85. Allais G, Bussone G, De Lorenzo C, et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci 2007;28(Suppl 2):S225–8.
86. Silberstein S, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261–9.
87. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133–48.
88. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001;41:248–56.
89. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037–49.
90. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998;51:307–9.
91. Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008;22:877–86.
92. Marcus DA, Bernstein CD, Sullivan EA, et al. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache 2010;50:551–6.
93. Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother 2014;15:2063–70.
94. MacGregor EA. Migraine management during menstruation and menopause. Continuum (Minneap Minn) 2015;21(4 Headache):990–1003.
95. Aegidius K, Zwart JA, Hagen K, et al. Oral contraceptives and increased headache prevalence: The Head-HUNT Study. Neurology 2006;66:349–53.
96. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261–6.
97. LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005;83:1875–7.
98. Sulak P,Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache 2007;47:27–37.
99. De Leo V, Scolaro V, Musacchio MC, et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011;96:917–20.
100. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J 2004;97:819–22.
101. Coffee AL, Sulak PJ, Hill AJ, et al. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt) 2014;23:310–7.
102. Vetvik KG, MacGregor EA, Lundqvist C, et al. Contraceptive-induced amenorrhea leads to reduced migraine frequency in women with menstrual migraine without aura. J Headache Pain 2014;15:30.
103. Sucato GS, Gerschultz KL. Extended cycle hormonal contraception in adolescents. Curr Opin Obstet Gynecol 2005;17:461–5.
104. Spector JT, Kahn SR, Jones MR, et al. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 2010;123:612–24.
105. Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010;74:628–35.
106. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914.
107. Gelfand AA, Fullerton HJ, Jacobson A, et al. Is migraine a risk factor for pediatric stroke? Cephalalgia 2015;35:1252–60.